Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 20/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 20/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL651040 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL651041 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL651630 | 0.82 | CHRNB2 (0.74) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL652614 | 0.81 | CHRNB2 (0.72) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL653976 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL653977 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL653978 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL652768 | 0.77 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL652769 | 0.77 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL652767 | 0.77 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558980-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C N C C S S C A R L COLLEZIONE NAZ DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2021-01-27 | — | — | EP | claimed |
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-10-27 | — | — | US | claimed |
| US-20200095232-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-03-26 | — | — | US | claimed |
| EP-3558980-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) | 2019-10-30 | — | — | EP | claimed |
| WO-2018115275-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-06-28 | — | — | WO | claimed |
| WO-2016128905-A1 | THIENOPYRROLE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-08-18 | — | — | WO | claimed |
| WO-2001057040-A1 | 6,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-08-09 | — | — | WO | claimed |
| WO-2024096066-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE | 第一工業製薬株式会社 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024096067-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN AND/OR INFLAMMATORY PAIN | 第一工業製薬株式会社 | 2024-05-10 | — | — | WO | disclosed |
| EP-4361148-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | Albius Sciences Alpha Private Limited (SG) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024071371-A1 | HETEROCYCLIC COMPOUND | ユビエンス株式会社 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024071370-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | 第一工業製薬株式会社 | 2024-04-04 | — | — | WO | disclosed |
| CN-117730079-A | Heterocyclyl-substituted polyheterazoles derivatives as medicaments for the treatment and/or prophylaxis of RSV infections | 亚博思生物科技(第一)有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES | 2004-03-04 | — | — | US | disclosed |
| WO-2004016604-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-1284976-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1178982-A1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LABORATORIES (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
| WO-2000071534-A1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LABORATORIES (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | CHRNB2 10/4885CHRNB4 13/4885CHRNA3 12/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNB4 15/4885CHRNA3 14/4885 |
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | NISCH, TK2, FDPS | CHRNB2 4721/4885CHRNB4 4797/4885CHRNA3 4455/4885 |
| US-20200095232-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | NISCH, TK2, FDPS | CHRNB2 4721/4885CHRNB4 4797/4885CHRNA3 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.